Liazal

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: Liazal
• 英文别名: (E)-but-2-enedioic acid;6-[(3-chlorophenyl)-imidazol-1-ylmethyl]-1H-benzimidazole
• 化学式: C21H17ClN4O4
• 分子量: 424.8
• InChiKey: UCJZBYIUZSFGPV-WLHGVMLRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.76
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  121
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients
  申请人：Rogers D. Robin

  公开号：US20070093462A1

  公开（公告）日：2007-04-26

  Disclosed are ionic liquids and methods of preparing ionic liquid compositions of active pharmaceutical, biological, nutritional, and energetic ingredients. Also disclosed are methods of using the compositions described herein to overcome polymorphism, overcome solubility and delivery problems, to control release rates, add functionality, enhance efficacy (synergy), and improve ease of use and manufacture.

  揭示了离子液体及制备活性药物、生物、营养和能量成分的离子液体组合物的方法。还揭示了利用本文描述的组合物的方法，以克服多型性、克服溶解度和输送问题、控制释放速率、增加功能性、增强功效（协同作用）以及改善易用性和制造工艺。
• [EN] NAPHTHYLENE DERIVATIVES AS CYTOCHROME P450 INHIBITORS<br/>[FR] DERIVES DE NAPHTYLENE CONSTITUANT DES INHIBITEURS DU CYTOCHROME P450
  申请人：OSI PHARM INC

  公开号：WO2005007631A1

  公开（公告）日：2005-01-27

  Compounds of the formula (I); and pharmaceutically acceptable salts thereof, wherein n1, n2, n3, n4, G 1,Q1, Z, R1, R2, R3, R4a, R4b, R5a, and R5b are defined herein, inhibit the cytochrome P450RAI enzyme and are useful for the treatment and/or prevention of various diseases and conditions which respond to treatment by retinoids and by naturally occurring retinoic acid.

  该式（I）的化合物及其药用盐，其中n1、n2、n3、n4、G 1、Q1、Z、R1、R2、R3、R4a、R4b、R5a和R5b在此处被定义，抑制细胞色素P450RAI酶，适用于治疗和/或预防对维甲酸类药物和天然存在的视黄酸有反应的各种疾病和病况。
• Naphthylene derivatives as cytochrome P450 inhibitors
  申请人：Smith Vanessa

  公开号：US20060009645A1

  公开（公告）日：2006-01-12

  Compounds of the formula and pharmaceutically acceptable salts thereof, wherein n 1 , n 2 , n 3 , n 4 , G 1 , Q 1 , Z, R 1 , R 2 , R 3 , R 4a , R 4b , R 5a , and R 5b are defined herein, inhibit the cytochrome P 450 RAI enzyme and are useful for the treatment and/or prevention of various diseases and conditions which respond to treatment by retinoids and by naturally occurring retinoic acid.

  该公式化合物及其药学上可接受的盐，其中n1、n2、n3、n4、G1、Q1、Z、R1、R2、R3、R4a、R4b、R5a和R5b在此处被定义，抑制细胞色素P450RAI酶，并可用于治疗和/或预防对维甲酸类药物和天然发生的维甲酸酸反应的各种疾病和症状。
• [EN] DUAL FUNCTIONING IONIC LIQUIDS AND SALTS THEREOF<br/>[FR] LIQUIDES IONIQUES À DOUBLE FONCTION ET SELS DE CEUX-CI
  申请人：UNIV ALABAMA

  公开号：WO2010078300A1

  公开（公告）日：2010-07-08

  Disclosed herein are ionic liquid compositions comprising active pharmaceutical, biological, and nutritional compounds, and methods of use. Further disclosed are compositions of matter including liquid ion pairs alone or in solution and their use; compositions of ionic liquids that are 'solvated,' for example, 'hydrated' and their uses.

  本文揭示了包括活性药物、生物学和营养化合物的离子液体组合物，以及其使用方法。进一步揭示了包括液态离子对的物质组合物，单独或溶解后使用；以及离子液体的“溶剂化”组合物，例如“水合”的组合物及其用途。
• Pharmaceutical preparation comprising an active dispersed on a matrix
  申请人：——

  公开号：US20040058896A1

  公开（公告）日：2004-03-25

  The present invention relates to the field of pharmaceutical technology and describes a novel advantageous preparation for an active ingredient. The novel preparation is suitable for producing a large number of pharmaceutical dosage forms. In the new preparation an active ingredient is present essentially uniformly dispersed in an excipient matrix composed of one or more excipients selected from the group of fatty alcohol, triglyceride, partial glyceride and fatty acid ester.

  本发明涉及制药技术领域，描述了一种新的有利的活性成分制备方法。这种新的制备方法适用于生产大量的药物剂型。在这种新的制备方法中，活性成分基本上均匀地分散在由脂肪醇、甘油三酯、部分甘油酯和脂肪酸酯等多种赋形剂中选择的一种或多种赋形剂组成的赋形剂基质中。